Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Teriparatide
Drug ID BADD_D02166
Description Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indications and Usage For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Marketing Status Discontinued; Prescription
ATC Code H05AA02
DrugBank ID DB06285
KEGG ID D06078
MeSH ID D019379
PubChem ID 16133850
TTD Drug ID D0YA2L
NDC Product Code 63557-0021; 69766-088; 32861-0008; 68594-030; 47781-652; 0002-8400; 52221-119; 41524-0010; 65129-1312
Synonyms Teriparatide | hPTH (1-34) | Human Parathyroid Hormone (1-34) | Parathar | Teriparatide Acetate | Forteo
Chemical Information
Molecular Formula C181H291N55O51S2
CAS Registry Number 52232-67-4
SMILES CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC( CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C( =O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)N C(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC (=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O) O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)N C(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervous system disorder17.02.10.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Osteosarcoma16.29.03.002; 15.09.03.010--Not Available
Osteosarcoma metastatic15.09.03.011; 16.29.03.003--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.003--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Sciatica17.10.03.001; 15.10.01.001--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Swelling08.01.03.015--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.007--Not Available
Tooth disorder07.09.05.001--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.001--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages